Tag - LRMR

Developments

Larimar reports positive initial data from OLE study of nomlabofusp in FA

Larimar Therapeutics (NASDAQ:LRMR) has announced positive initial results from its ongoing open-label extension (OLE) study evaluating daily subcutaneous injections of 25 mg of nomlabofusp, either self-administered or...

December 16, 2024

Markets

WB ups Larimar to OP after Phase 2 clinical hold lifted

William Blair upgraded Larimar Therapeutics (NASDAQ:LRMR) to “outperform” after the FDA approved the company’s proposed Phase 2 study design for CTI-1601 in Friedreich’s ataxia (FA), enabling a return to clinical...

September 19, 2022

Markets

WB starts Larimar Therapeutics at OP; fair value estimate $29

William Blair initiated coverage of Larimar Therapeutics (NASDAQ:LRMR) with an “outperform” rating and fair value estimate of $29. The stock closed at $15.44 on Jan. 29. Larimar is developing intracellular-targeted...

February 1, 2021

Tag - LRMR

Larimar reports positive initial data from OLE study of nomlabofusp in FA

WB ups Larimar to OP after Phase 2 clinical hold lifted

WB starts Larimar Therapeutics at OP; fair value estimate $29

General

More